JP2013538040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538040A5 JP2013538040A5 JP2013514398A JP2013514398A JP2013538040A5 JP 2013538040 A5 JP2013538040 A5 JP 2013538040A5 JP 2013514398 A JP2013514398 A JP 2013514398A JP 2013514398 A JP2013514398 A JP 2013514398A JP 2013538040 A5 JP2013538040 A5 JP 2013538040A5
- Authority
- JP
- Japan
- Prior art keywords
- adb
- fiber
- fiber polypeptide
- seq
- multimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 claims description 166
- 229920001184 polypeptide Polymers 0.000 claims description 85
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 66
- 210000000981 epithelium Anatomy 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 102000005707 Desmoglein 2 Human genes 0.000 claims description 17
- 108010045583 Desmoglein 2 Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- 239000000539 dimer Substances 0.000 claims description 9
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 9
- 239000012216 imaging agent Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 206010056375 Bile duct obstruction Diseases 0.000 claims description 2
- 206010004637 Bile duct stone Diseases 0.000 claims description 2
- 206010007882 Cellulitis Diseases 0.000 claims description 2
- 201000009331 Choledocholithiasis Diseases 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 208000001130 gallstones Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000000277 pancreatic duct Anatomy 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 208000014644 Brain disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000013718 rectal benign neoplasm Diseases 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- 206010029098 Neoplasm skin Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 201000011523 endocrine gland cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000025402 neoplasm of esophagus Diseases 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 208000025421 tumor of uterus Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35365210P | 2010-06-10 | 2010-06-10 | |
| US61/353,652 | 2010-06-10 | ||
| US201161430091P | 2011-01-05 | 2011-01-05 | |
| US61/430,091 | 2011-01-05 | ||
| US201161470663P | 2011-04-01 | 2011-04-01 | |
| US61/470,663 | 2011-04-01 | ||
| PCT/US2011/040053 WO2011156761A1 (en) | 2010-06-10 | 2011-06-10 | Methods and systems for adenovirus interaction with desmoglein 2 (dsg2) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176242A Division JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538040A JP2013538040A (ja) | 2013-10-10 |
| JP2013538040A5 true JP2013538040A5 (enExample) | 2014-07-24 |
| JP6499825B2 JP6499825B2 (ja) | 2019-04-10 |
Family
ID=45096374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514398A Active JP6499825B2 (ja) | 2010-06-10 | 2011-06-10 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
| JP2016176242A Pending JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176242A Pending JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8722853B2 (enExample) |
| EP (1) | EP2580234B1 (enExample) |
| JP (2) | JP6499825B2 (enExample) |
| KR (2) | KR101915699B1 (enExample) |
| AU (1) | AU2011265260C1 (enExample) |
| WO (1) | WO2011156761A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013191675A1 (en) * | 2012-06-18 | 2013-12-27 | Empire Technology Development Llc | Ionizing radiation detector for use with endoscopic ultrasound |
| US20150246949A1 (en) * | 2012-09-25 | 2015-09-03 | University Of Washington Through Its Center For Commercialization | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| JP2016538327A (ja) * | 2013-09-24 | 2016-12-08 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用 |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| IT201600077232A1 (it) * | 2016-07-22 | 2018-01-22 | Bio Optica Milano S P A | Una preparazione liquida acquosa per la conservazione di un campione istologico |
| EP3333176A1 (en) | 2016-12-09 | 2018-06-13 | Universite De Geneve | Peptidic protein kinase c inhibitors and uses thereof |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US20200347101A1 (en) * | 2018-01-25 | 2020-11-05 | Pai Life Sciences, Inc. | Conjugatable desmoglein 2 (dsg2) binding proteins and uses therefor |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CA3102328A1 (en) | 2018-06-12 | 2019-12-19 | Universite De Geneve | Peptidic protein kinase c inhibitors and uses thereof |
| CN110616199A (zh) * | 2019-06-26 | 2019-12-27 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型重组人7型腺病毒及其制备方法和应用 |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| WO2021072112A1 (en) | 2019-10-09 | 2021-04-15 | Hdt Bio Corp. | Detection of desmoglein-2 in cancers of epithelial origin |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法 |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| KR102969181B1 (ko) * | 2022-03-04 | 2026-05-26 | (주)큐리진 | 순환종양세포 검출을 위한 아데노바이러스 5/3 형 |
| CN115400121B (zh) * | 2022-04-29 | 2023-05-23 | 佛山病原微生物研究院 | 一种snx-2112在制备用于抗腺病毒感染的药物中的用途 |
| CN114652726B (zh) * | 2022-04-29 | 2024-03-19 | 暨南大学 | Biib021在制备预防和/或治疗腺病毒感染的药物中的应用 |
| WO2025081013A1 (en) * | 2023-10-12 | 2025-04-17 | Hdt Bio Corp. | Junction opener protein and nanoparticle compositions and uses thereof |
| CN118421565B (zh) * | 2024-03-21 | 2024-11-29 | 中国人民解放军军事科学院军事医学研究院 | 重组骨软骨干细胞及其制备方法与应用 |
| CN119055642A (zh) * | 2024-07-23 | 2024-12-03 | 湖北工业大学 | Ganetespib化合物在制备抗人类腺病毒7型病毒药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
| KR20010074429A (ko) | 1998-02-17 | 2001-08-04 | 피터 브이. 오`네일 | 섬유 교체 단백질을 함유하는 변형된 아데노바이러스 |
| AU772630B2 (en) | 1999-01-14 | 2004-05-06 | Novartis Ag | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| CA2392272A1 (fr) | 1999-11-25 | 2001-05-31 | Transgene S.A. | Fibre adenovirable modifiee et utilisations |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| EP1531757B1 (en) | 2002-07-19 | 2016-09-07 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| WO2005040333A2 (en) * | 2003-10-24 | 2005-05-06 | National Research Council Of Canada | Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism |
| US8242222B2 (en) | 2008-03-31 | 2012-08-14 | Shiseido Company, Ltd. | Polysiloxane, acrylic compound and vinylic compound |
-
2011
- 2011-06-10 US US13/158,246 patent/US8722853B2/en active Active
- 2011-06-10 JP JP2013514398A patent/JP6499825B2/ja active Active
- 2011-06-10 AU AU2011265260A patent/AU2011265260C1/en active Active
- 2011-06-10 KR KR1020137000726A patent/KR101915699B1/ko active Active
- 2011-06-10 KR KR1020187031687A patent/KR20180122043A/ko not_active Withdrawn
- 2011-06-10 EP EP11736215.2A patent/EP2580234B1/en active Active
- 2011-06-10 WO PCT/US2011/040053 patent/WO2011156761A1/en not_active Ceased
-
2013
- 2013-10-29 US US14/066,353 patent/US9200041B2/en active Active
-
2016
- 2016-09-09 JP JP2016176242A patent/JP2016202188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016110826A (ru) | Белки, связывающие десмоглеин 2 (dsg2), и их применение | |
| JP2015532265A5 (enExample) | ||
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| US12122844B2 (en) | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | |
| JP6144771B2 (ja) | Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物 | |
| JP2016518325A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| RU2018114904A (ru) | Антитело против garp | |
| WO2016106158A1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2013527761A5 (enExample) | ||
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| JP2015529641A5 (enExample) | ||
| KR102935581B1 (ko) | 암을 치료하기 위한 플라스미드 작제물 및 사용 방법 | |
| JP2020526503A5 (enExample) | ||
| JP2009518024A5 (enExample) | ||
| JP2024521472A5 (enExample) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| ITRM20100577A1 (it) | Immunoterapia contro il recettore erbb-3 | |
| US20200407420A1 (en) | Her-1, her-3 and igf-1r compositions and uses thereof | |
| CN104717980A (zh) | 干细胞增强疗法 | |
| JP2010500006A5 (enExample) | ||
| TWI924623B (zh) | 頭頸癌之治療 | |
| CN103561761A (zh) | 用于使用抗-整合素改善抗血管生成疗法的方法和组合物 | |
| RU2015154985A (ru) | Способы лечения рака |